The stock of Context Therapeutics Inc (CNTX) has gone up by 13.44% for the week, with a -5.50% drop in the past month and a -24.30% drop in the past quarter. The volatility ratio for the week is 6.30%, and the volatility levels for the past 30 days are 6.63% for CNTX. The simple moving average for the last 20 days is 7.44% for CNTX stock, with a simple moving average of -45.62% for the last 200 days.
Is It Worth Investing in Context Therapeutics Inc (NASDAQ: CNTX) Right Now?
The 36-month beta value for CNTX is also noteworthy at 1.85. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CNTX is 57.81M, and at present, short sellers hold a 3.86% of that float. The average trading volume of CNTX on June 26, 2025 was 247.17K shares.
CNTX) stock’s latest price update
Context Therapeutics Inc (NASDAQ: CNTX)’s stock price has increased by 13.72 compared to its previous closing price of 0.58. However, the company has seen a 13.44% increase in its stock price over the last five trading sessions. seekingalpha.com reported 2025-06-10 that Context Therapeutics offers a compelling long opportunity, with three differentiated bispecific T-cell engagers targeting solid tumors and strong early-stage clinical momentum. The company is well-capitalized, with $89 million in cash and access to additional funding, supporting operations through key Phase I data milestones into 2027. CNTX trades at a deep discount to book value and is technically oversold; positive clinical data could trigger a significant re-rating and share price upside.
Analysts’ Opinion of CNTX
JMP Securities, on the other hand, stated in their research note that they expect to see CNTX reach a price target of $4. The rating they have provided for CNTX stocks is “Mkt Outperform” according to the report published on January 08th, 2025.
D. Boral Capital gave a rating of “Buy” to CNTX, setting the target price at $9 in the report published on November 25th of the previous year.
CNTX Trading at -10.68% from the 50-Day Moving Average
After a stumble in the market that brought CNTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.19% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CNTX starting from Lehr Martin A., who purchase 100,000 shares at the price of $0.70 back on Jun 09 ’25. After this action, Lehr Martin A. now owns 920,190 shares of Context Therapeutics Inc, valued at $70,080 using the latest closing price.
Levit Alex C., the Chief Legal Officer, Corp. Sec of Context Therapeutics Inc, purchase 20,000 shares at $0.58 during a trade that took place back on Jun 06 ’25, which means that Levit Alex C. is holding 29,000 shares at $11,520 based on the most recent closing price.
Stock Fundamentals for CNTX
The total capital return value is set at -0.35. Equity return is now at value -55.59, with -53.13 for asset returns.
Based on Context Therapeutics Inc (CNTX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -78.6.
Currently, EBITDA for the company is -26.67 million with net debt to EBITDA at 2.82. The liquidity ratio also appears to be rather interesting for investors as it stands at 48.80.
Conclusion
In summary, Context Therapeutics Inc (CNTX) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
